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Key messages
What is already known about this subject?
 ► clinical trials support equivalence of originator prod-
ucts and biosimilars for etanercept and infliximab.
 ► real-world studies among biologics-naïve patients 
with spondyloarthritis (Spa) are lacking.
What does this study add?
 ► this observational study from five nordic biologic 
registries showed comparable patient characteristics 
and retention to treatment among biologics-naïve 
patients with Spa treated with originators versus 
biosimilars (infliximab or etanercept).
How might this impact on clinical practice?
 ► these real-world data indicate similar effectiveness 
of originator and biosimilar products in Spa.
AbstrAct
Objective although clinical trials support equivalence 
of originator products and biosimilars for etanercept 
and infliximab, real-world studies among biologics-
naïve patients with spondyloarthritis (Spa) are lacking. 
the objectives were to compare treatment retention 
in biologics-naïve patients with Spa starting either 
the originator product or a biosimilar of infliximab and 
etanercept, and to explore the baseline characteristics of 
these patients.
Methods Patients with Spa (ankylosing spondylitis/
non-radiographical axial Spa/undifferentiated Spa), 
starting infliximab or etanercept as their first-ever 
biological disease-modifying antirheumatic drug during 
January 2014–June 2017 were identified in five nordic 
biologics–rheumatology registers. Baseline characteristics 
were retrieved from each registry; comorbidity data were 
identified through linkage to national health registers. 
country-specific data were pooled, and data on infliximab 
and etanercept were analysed separately. comparisons of 
treatment retention between originators and biosimilars 
were assessed through survival probability curves, 
retention rates (2 years for infliximab/1 year for etanercept) 
and Hazard ratios (Hr).
Results We included 1319 patients starting infliximab 
(24% originator/76% biosimilar), and 1015 patients 
starting etanercept (49% originator/51% biosimilar). 
Baseline characteristics were largely similar for the 
patients treated with the originators compared with the 
corresponding biosimilars. Survival probability curves 
were highly similar for the originator and its biosimilar, as 
were retention rates: infliximab 2-year retention originator, 
44% (95% ci 38% to 50%)/biosimilar, 46% (95% ci: 42% 
to 51%); and etanercept 1-year retention originator, 66% 
(95% ci 61% to 70%)/biosimilar, 73% (95% ci 68% to 
78%). Hrs were not statistically significant.
Conclusion this observational study of biologics-naïve 
patients with Spa from five nordic countries showed 
similar baseline characteristics and very similar retention 
rates in patients treated with originators versus biosimilars, 
for both infliximab and etanercept, indicating comparable 
effectiveness in clinical practice.
InTROduCTIOn
The first infliximab biosimilar (CT-P13) was 
introduced on the European market in 2014, 
followed by the first etanercept biosimilar 
(SB4) in 2015. Before marketing, efficacy 
and safety of biosimilars versus originators 
were explored in randomised controlled 
trials (RCTs). For infliximab, the initial 
RCTs, PLANETRA1 and PLANETAS,2 were 
conducted in rheumatoid arthritis (RA) and 
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ankylosing spondylitis (AS), respectively. In the PLAN-
ETAS study, the primary outcome was pharmacokinetic 
equivalence rather than efficacy.2 For etanercept, only 
patients with RA were studied,3 and so far, no randomised 
trials have been conducted for SB4 in other indications 
than RA. However, the regulatory approvals of CT-P13 
and SB4 were extrapolated to all of the approved indi-
cations for the originator products, thus including the 
spondyloarthritis (SpA) disease entities.4
Outcomes following a switch from successful treat-
ment with the originator to the corresponding biosim-
ilar drugs (so called non-medical switch) were studied 
in premarketing extension studies.5–7 Postmarketing, 
one independent RCT (NOR-SWITCH8) compared 
safety and effectiveness of infliximab originator (INF) 
with CT-P13 in routine care. Patients with six different 
inflammatory disorders (including 121 patients with SpA 
or psoriatic arthritis (PsA)) were randomised either to 
continue with INF or to switch to CT-P13, with no differ-
ences in outcomes at week 52. Further, several observa-
tional studies including patients with SpA have assessed 
infliximab switch,9–13 in some cases using comparisons 
with historical cohorts treated with infliximab. Similar 
studies have also been performed for etanercept.14 The 
outcome in these observational studies has differed, 
generally (but not exclusively15) slightly disfavouring the 
biosimilar product. This has largely been attributed to a 
nocebo effect, although the evidence for such an effect 
has been disputed.16 Furthermore, the observed differ-
ences could potentially be due to the drugs performing 
differently in a clinical setting as opposed to the highly 
selected patients included in RCTs.17
Large observational studies in SpA comparing biolog-
ics-naïve patients starting biological disease-modifying 
antirheumatic drug (bDMARD) treatment with an orig-
inator versus treatment with their respective biosimilar 
during the same calendar time period are thus lacking. 
Such studies are of particular importance since the only 
study leading to registration that included patients with 
AS (PLANETAS2) did not have efficacy as its primary 
outcome.
The market entry of the biosimilars has been accom-
panied by a significant reduction in costs in many coun-
tries, which has spurred a transition from the originator 
products towards their biosimilars. In the Nordic region 
(Denmark, Iceland, Finland, Norway and Sweden), the 
strategies for transition have differed markedly across 
the countries, depending primarily on differences in 
pricing.18 Within Sweden, the uptake was further diversi-
fied by separate tender processes in different counties.19 
As a result, during the period 2014–2017, biologics-naïve 
patients with SpA in the Nordic countries have started 
both originator and biosimilar versions of infliximab 
and of etanercept. This offers a unique opportunity 
to compare the performance of these drugs in biolog-
ics-naïve patients with minimal risk of a nocebo effect.
The main objective of this study was therefore to 
compare the treatment retention for infliximab and 
etanercept originator (INF and ETN) products with their 
respective biosimilars (CT-P13 and SB4), in bio-naïve 
patients with SpA starting treatment in 2014–2017, and 
furthermore to explore the baseline characteristics of 
treated patients toassess comparability.
PaTIenTs and MeTHOds
study design
This is an observational cohort study.
Biologics in the nordic countries
The strategies for implementing biosimilars in routine 
care have varied between Nordic countries. Thus, 
the countries have applied different policies towards 
switching and choice of biosimilars/originators in biolog-
ics-naïve patients. In Denmark, it was mandatory to switch 
all patients treated with INF or ETN to their respective 
biosimilars, when the biosimilars were marketed.9 14 20 In 
Sweden, the strategies for both new starts and switching 
differed across the different counties,19 and in Finland, 
INF or a biosimilar was used based on exclusive pricing 
negotiations made in individual hospital districts, whereas 
the first etanercept biosimilar was not reimbursed in 
Finland until January 2018. In Iceland, the least expensive 
bDMARDs are recommended as first-line drugs based on 
an annual tendering process under the authority of the 
Icelandic Health Insurance (state insurance company). 
Switching from INF to its biosimilars is also recommended 
when the biosimilar is marketed in Iceland (biosimilar 
to etanercept was not marketed in Iceland at the study 
time). In Norway, non-medical switching policies differ 
between hospitals, whereas the decision between biosim-
ilars/originators in biologics-naïve patients is decided by 
the annual national tender.
Case definitions
Patients with SpA starting infliximab or etanercept (orig-
inator or biosimilar) as their first bDMARD at any time 
between 1 January 2014 and 30 June 2017 were identified 
from the national biologics registers in Sweden (ARTIS), 
Denmark (DANBIO), Finland (ROB-FIN), Iceland 
(ICEBIO), as well as a regional biologics register in 
Norway (NOR-DMARD). In all these registries, informa-
tion on patient characteristics, disease activity and treat-
ment with DMARDs is registered prospectively as part of 
routine care as previously described.18
The registers define the SpA diagnoses differently, 
either based on International Classification of Diseases, 
10th Revision (ICD-10) codes or on clinical diagnoses. 
SpA was therefore defined as having either an ICD-10 
code for AS (M45) or undifferentiated SpA (M46.0, 
M46.1, M46.8 and M46.9), or a clinical diagnosis of AS 
or non-radiographical axial SpA. Patients with a primary 
diagnosis of PsA were excluded, but an additional diag-
nosis of cutaneous psoriasis (identified from the national 
patient registries; see description below) was allowed.
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Patient characteristics
Patient characteristics at baseline (ie, when starting the 
first bDMARD treatment) were identified in the biologic 
registries according to the visit closest (within −30 days to 
+14 days) to the start date of the bDMARD in question. 
Characteristics included SpA disease duration, patient 
pain score on a visual analogue scale (VAS) (0–100 mm), 
patient global score on a VAS (0–100 mm), C reactive 
protein (CRP) level (mg/L), Ankylosing Spondylitis 
Disease Activity Score (ASDAS), Bath Ankylosing Spon-
dylitis Disease Activity Index (BASDAI) and Bath Anky-
losing Spondylitis Functional Index (BASFI). Further-
more, concomitant use of a conventional synthetic 
disease-modifying antirheumatic drug (csDMARD) (yes/
no) was registered.
Linkage to a National Patient Register was available in 
Denmark21 and Sweden,22 from which data were retrieved 
on inpatient and outpatient contacts for diagnoses of 
the extra-articular SpA manifestations of psoriasis (ICD-
10: L40) and inflammatory bowel disease (ICD-10: K50, 
K51) in the last 10 years prior to baseline. In Finland, a 
similar linkage was made to the Care Register (HILMO) 
provided by the National Institute for Health and Welfare 
(THL).
Treatment retention
Start of follow-up was defined as the start date of the first 
bDMARD. End of follow-up was defined as the date of 
treatment discontinuation (for those who did discon-
tinue), or on censoring defined as the first of death or the 
end of the study period (30 June 2017). For patients who 
switched from the originator/biosimilar to its biosimilar/
originator, follow-up was censored at the switch date.
Treatment response
Patient global and patient pain score, BASDAI, ASDAS, 
CRP and BASFI were assessed at baseline and at 6 months 
after the start of follow-up, defined as the visit closest to 
180 days after treatment start (within days 90–270).
statistics
Baseline characteristics are presented as means or propor-
tions. For each of the comparative analyses described 
further below, available data from the five Nordic coun-
tries were pooled.
Treatment retention was compared between the orig-
inator and biosimilar products through crude survival 
probability curves, truncated at 1 year of follow-up for 
etanercept and at 2 years for infliximab, with a crude 
statistical comparison through log-rank test. For etaner-
cept, the assessment of treatment retention was limited 
to 1 year since SB4 was introduced 1 year after CT-P13, 
resulting in few patients remaining at risk and still treated 
after 1 year. Retention rates were calculated at 1 year for 
etanercept and at 1 and 2 years for infliximab.
HRs for discontinuing treatment were estimated using 
Cox proportional hazard models: crude and in three 
models adjusting for baseline values of (1) age, sex and 
concomitant csDMARD (yes/no/missing); (2) age, sex, 
csDMARD and CRP (categorised in quartiles); and (3) 
age, sex, csDMARD and patient global score (categorised 
in quartiles). Missing values due to missing information 
or a missing visit at baseline were added as a separate 
category. Adjusting for CRP and patient global score 
rather than the disease-specific activity measures ASDAS 
or BASDAI was chosen due to a higher proportion of 
missing data for the latter. No evidence of departure 
from the proportionality assumption was observed in 
these models.
The proportions of patients contributing data at 
baseline and at 6 months of follow-up are presented in 
online supplementary table S1. Due to a high propor-
tion of missing disease activity measures, no statistical 
comparisons were made; only group means and SDs are 
presented.
Patient and public involvement
Within the Nordic collaboration performing this study, 
patient representatives were involved in the planning 
and development of the research questions and the study 
design.
ResulTs
In total, 2334 patients with SpA were included, of whom 
1319 started infliximab and 1015 started etanercept as 
their first biological treatment. There were no clinically 
relevant differences in baseline characteristics and demo-
graphics between the originator and corresponding 
biosimilar cohorts, apart from a higher proportion of 
patients using concomitant csDMARD in the originator 
cohorts of both infliximab and etanercept (table 1). The 
use of biosimilars versus originators differed markedly 
between the countries. In Finland and Iceland, SB4 was 
not available during the time period.
Treatment retention
The survival probability curves for the first 2 years of 
treatment were similar for CT-P13 and INF (p value of 
0.59), and so were 1 year probability curves for ETN and 
SB4 (p value of 0.18) (figure 1A,B).
The 1-year retention rates for INF and CT-P13 were 
comparable: 1-year INF, 62% (95% CI 57% to 68%); 
CT-P13, 63% (95% CI 60% to 66%); 2-year INF, 44% 
(95% CI 38% to 50%), and CT-P13, 46% (95% CI: 42% 
to 51%). Likewise, the 1-year retention rates for ETN and 
SB4 were comparable: ETN, 66% (95% CI 61% to 70%) 
and SB4, 73% (95% CI 68% to 78%).
The proportional hazard analyses showed no statisti-
cally significant difference in treatment retention when 
comparing the biosimilars with their respective orig-
inator products, neither in crude nor in adjusted anal-
yses (table 2). The results indicated a 5% decrease in 
risk of discontinuation favouring CT-P13 compared with 
INF, and a 15% decrease for SB4 compared with ETN; 
however, in neither case did the 95% CIs confirm a statis-
tically significant decrease in risk. Adjusting for baseline 
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Table 1 Baseline characteristics and demographics of infliximab-treated and etanercept-treated patients with SpA and 
reason for discontinuation
Infliximab n=1319 Etanercept n=1015
INF (n=320) CT-P13 (n=999) ETN (n=493) SB4 (n=522)
Age (years) 42 (14) 42 (13) 41 (14) 41 (14)
Disease duration (years) 13 (12) 10 (11) 12 (12) 11 (12)
Sex, men, n (%) 183 (57) 576 (58) 235 (48) 261 (50)
AS, n (%) 183 (57) 461 (46) 204 (41) 199 (38)
nraxSpA or uSpA, n (%) 137 (43) 538 (54) 289 (59) 323 (62)
Psoriasis (%)* 6 3 7 5
Inflammatory bowel disease (%)* 10 11 2 2
CRP (mg/L) 15 (21) 13 (22) 11 (18) 10 (15)
Patient global (mm) 59 (24) 64 (24) 57 (22) 59 (23)
Patient pain (mm) 62 (23) 59 (24) 59 (24) 59 (22)
ASDAS 3.4 (1.0) 3.4 (1.0) 3.1 (0.9) 3.0 (0.9)
BASDAI (mm) 6.0 (2.0) 5.6 (2.0) 5.4 (2.0) 5.4 (1.9)
BASFI (mm) 4.4 (2.5) 4.8 (2.4) 4.1 (2.4) 4.1 (2.5)
Concomitant csDMARD, n (%) 96 (44) 238 (31) 98 (29) 85 (22)
Country
  Iceland, n (%) 5 (2) 70 (7) 8 (2) 0 (0)
  Norway, n (%) 2 (1) 104 (10) 7 (1) 20 (4)
  Finland, n (%) 21 (7) 38 (4) 94 (19) 0 (0)
  Denmark, n (%) 19 (6) 546 (55) 19 (4) 79 (15)
  Sweden, n (%) 273 (85) 241 (24) 365 (74) 423 (81)
Reason for discontinuation
  Adverse event, n (%) 48 (15) 131 (13) 33 (7) 22 (4)
  Death, n (%) 1 (0) 0 (0) 0 (0) 1 (0)
  Inefficacy, n (%) 61 (19) 139 (14) 91 (19) 45 (9)
  Pregnancy, n (%) 3 (1) 4 (0) 5 (1) 0 (0)
  Remission, n (%) 1 (0) 0 (0) 1 (0) 0 (0)
  Non-medical switch, n (%) 46 (14) 23 (2) 81 (16) 1 (0)
  Other, n (%) 51 (16) 70 (7) 64 (13) 22 (4)
Numbers are means (SD) unless otherwise stated.
*Comorbidities available from Sweden, Denmark and Finland.
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity 
Index;BASFI, Bath Ankylosing Spondylitis Function Index; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying 
antirheumatic drug; CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab originator; nraxSpA, non-radiographical axial 
spondyloarthritis; SB4, etanercept biosimilar; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.
use of concomitant csDMARD, which did differ between 
the originators and biosimilars, did not change the 
results.
disease activity at baseline and 6 months
Table 3 presents mean values (SD) for patient global and 
pain scores, BASDAI, BASFI, CRP and ASDAS at baseline 
and at 6 months of follow-up. At both baseline and 6 months 
of follow-up, mean values showed similar disease activity for 
the two biosimilars compared with their originators.
dIsCussIOn
In this observational study of 2334 biologics-naïve patients 
with SpA initiating treatment with infliximab or etaner-
cept, we found highly similar treatment retentions for 
the originator products compared with their biosimilars. 
The characteristics of the patients receiving the origina-
tors and the biosimilars were also similar, suggesting that 
the cohorts were comparable. Thus, these results support 
the equivalence of the treatments.
Due to the complex manufacturing process, a biosim-
ilar product is never 100% identical to its originator.23 
Thus, although equivalent efficacy and safety of the 
biosimilar must be demonstrated before marketing, 
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Figure 1 Treatment retention in patients treated with infliximab or etanercept biosimilar and originator products. Kaplan-Meier 
curves of treatment retention for (A) CT-P13 and INF, and (B) SB4 and ETN. CT-P10, infliximab biosimilar; ETN, etanercept 
originator; INF, infliximab originator; SB4, etanercept biosimilar.
it has been debated how to implement biosimilars in 
routine care.24 Furthermore, concerns have been raised 
regarding extrapolation across indications.
Several studies have assessed the effect of switch to a 
biosimilar, performed among patients treated with the 
originators, some including patients with SpA. The first 
of these were the extension studies of the initial RCTs5–7 
and the RCT study NOR-SWITCH8 (now with an exten-
sion25), followed by a small observational study,10 none 
of which found differences in effectiveness following 
a switch from INF to CT-P13 or ETN to SB4. However, 
in observational studies investigating the effect of 
non-medical switching, it is challenging to find a compa-
rable control group, since only an RCT design (such 
as NOR-SWITCH) can eliminate channelling (towards 
treatment) completely. In one large observational study 
assessing infliximab switch, a comparison was performed 
with a historical INF cohort, and a slightly lower retention 
rate was described for the patients switched to CT-P13.9 
Similar results were found in a large observational study 
of ETN to SB4 switch.14 In another study, 89 patients (75 
with SpA) switching from INF to CT-P13 were compared 
with 29 infliximab-naïve patients starting CT-P13 and 82 
historical patients starting INF, also finding a lower reten-
tion rate for the switched patients compared with the 
other two groups.12 Yet another small study evaluating 
the INF to CT-P13 switch found a discontinuation rate of 
24% during 6 months of follow-up after switching.11 In 
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Table 2 HRs for discontinuing treatment with (A) biosimilar 
versus originator (reference) infliximab, (B) biosimilar versus 
originator (reference) etanercept
A.
CT-P13 versus INF
HR (95% CI)
B.
SB4 versus ETN
HR (95% CI)
Crude 0.95 (0.79 to 1.15) 0.82 (0.63 to 1.07)
Adjusted*
  Sex, age, 
csDMARD
0.94 (0.78 to 1.14) 0.84 (0.64 to 1.09)
  Sex, age, 
csDMARD, CRP
0.94 (0.78 to 1.14) 0.84 (0.65 to 1.09)
  Sex, age, 
csDMARD, patient 
global
0.93 (0.77 to 1.13) 0.84 (0.65 to 1.09)
*Adjusted for baseline characteristics, all patients are included 
in the multivariable analyses due to the categorisation of the 
variables (see Patients and methods section).
CRP, C reactive protein;csDMARD, conventional synthetic 
disease-modifying antirheumatic drug; CT-P13, infliximab 
biosimilar; ETN, etanercept originator; INF, infliximab originator; 
SB4, etanercept biosimilar.
Table 3 Mean disease activity at baseline and after 6 months of follow-up for patients treated with infliximab or etanercept
Disease activity, mean (SD)
Infliximab Etanercept
INF CT-P13 ETN SB4
VAS patient, pain (mm)
  Baseline 62 (23) 59 (24) 59 (24) 59 (22)
  6 months 32 (26) 33 (28) 30 (27) 28 (25)
VAS patient, global (mm)
  Baseline 59 (24) 64 (24) 57 (22) 59 (23)
  6 months 33 (26) 37 (30) 30 (27) 30 (24)
ASDAS
  Baseline 3.37 (1.02) 3.35 (0.97) 3.05 (0.90) 2.98 (0.94)
  6 months 1.95 (1.15) 2.03 (1.18) 1.67 (1.01) 1.65 (0.90)
BASDAI
  Baseline 5.97 (2.00) 5.61 (2.03) 5.36 (2.01) 5.36 (1.93)
  6 months 3.18 (2.32) 3.37 (2.61) 2.95 (2.50) 2.72 (2.09)
BASFI
  Baseline 4.38 (2.51) 4.79 (2.38) 4.06 (2.36) 4.09 (2.48)
  6 months 2.37 (2.50) 3.01 (2.67) 2.10 (2.22) 1.74 (1.88)
CRP
  Baseline 15 (21) 13 (22) 11 (18) 10 (15)
  6 months 6 (11) 5 (11) 4 (5) 3 (4)
Numbers are means (SD) for patients with available data at the specific time point. The proportion of patients contributing data is shown 
in online supplementary table S1.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath 
Ankylosing Spondylitis Functional Index; CRP, C reactive protein;CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab 
originator; SB4, etanercept biosimilar; VAS, visual analogue scale.
both of these latter studies,11 12 the increased discontin-
uation rate for the biosimilar appeared to be driven by 
a subjective patient perception of disease activity rather 
than objective measures, supporting a nocebo effect. 
Yet another study, assessing the infliximab switch, esti-
mated a ‘nocebo response’ of 13%, further suggesting 
that a shared decision-making and patient involvement 
in the switch process may lead to favourable retention 
rates.13 The observational studies assessing the effect of 
switching, either comparing with non-switched patients 
or comparing with a historical cohort, are thus hampered 
by potential confounders, such as patients’ expecta-
tions towards the switch (nocebo), which cannot easily 
be disentangled from actual differences in the effect, 
or confounding by indication/channelling towards the 
choice of drug. Hence, such studies do not necessarily 
reflect the true biosimilar drug effect.
A strength of the present study is that confounders, 
such as nocebo related to the context of switching from 
a stable ongoing treatment with an originator to its 
(cheaper) biosimilar, should be minimised in a bionaïve 
population. Another strength is that the pooling of data 
from the different countries ought to reduce the risk 
of country-specific channelling towards originators or 
biosimilars.
Our study also has some limitations. First, the pooled 
data from the five different Nordic countries did not 
allow for a direct comparison of effectiveness (eg, 
response rates) of the originators and the biosimi-
lars due to missing data. However, the similarities in 
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the mean disease activity measures at baseline and at 
6 months of follow-up, together with the very similar 
drug retention, suggest similar effectiveness. Another 
potential problem is that not all countries contributed 
to all treatment arms. We have previously explored 
treatment of SpA with bDMARDs in the Nordic coun-
tries and demonstrated that the most notable differ-
ence is in the use of concomitant csDMARDs, which we 
have adjusted for in the analyses.18
In conclusion, in this large, international, biolog-
ic-naïve SpA cohort, we found equivalent treatment 
retentions for infliximab and etanercept biosimilars 
compared with their originators, indicating compa-
rable effectiveness in routine care.
author affiliations
1Department of rheumatology and inflammation research, Sahlgrenska academy, 
University of gothenburg, gothenburg, Sweden
2DanBiO and copenhagen center for arthritis research (cOPecare), center for 
rheumatology and Spine Diseases, centre of Head and Orthopedics, rigshospitalet 
glostrup, glostrup, Denmark
3Department of clinical Medicine, Faculty of Health and Medical Sciences, 
University of copenhagen, copenhagen, Denmark
4clinical epidemiology Unit, Department of Medicine Solna, Karolinska institutet, 
Stockholm, Sweden
5Department of Medicine, Helsinki University and Helsinki University Hospital, 
Helsinki, Finland
6rheumatology, Diakonhjemmet Hospital, Oslo, norway
7centre for rheumatology research, University Hospital and Faculty of Medicine, 
University of iceland, reykjavik, iceland
8Pharmaceuticals Pricing Board, Ministry of Social affairs and Health, Helsinki, 
Finland
9Zitelab aps, copenhagen, Denmark
10Department of rheumatology, University Hospital, reykjavik, iceland
acknowledgements We thank all the departments contributing to the clinical 
data collection in the participating biologic registers, as well as the participating 
patient representatives. thank you to Frank Mehnert, clinical epidemiology, aarhus 
University Hospital, aarhus, Denmark, who contributed management of data from 
the Danish national Patient registry.
Contributors Ul, Bg and lJ contributed to the study design. DDg performed the 
analysis of raw data. all authors contributed to the interpretation of the results and 
in the preparation of the manuscript.
Funding this study was partly funded by grants from nord-Forsk and FOreUM.
Competing interests Bg: grant/research support from Biogen, Pfizer and abbVie. 
Ja: Karolinska institutet (through Ja) has or has had research agreements with the 
following pharmaceutical companies, mainly in the context of the artiS national 
safety monitoring programme for rheumatology biologicals: abbvie, BMS, MSD, 
eli lilly, Pfizer, roche, Samsung Bioepis and UcB; Karolinska institutet has alo 
received remuneration for Ja participating in ad boards arranged by lilly, novartis 
and Pfizer. Dn: grant/research support from MSD, Pfizer; consultant for abbVie, 
BMS, MSD, novartis, roche, Pfizer and UcB; speakers' bureau: novartis and UcB. 
SP: consultant for novartis; speakers' bureau: lilly. MH: grant/research support 
from BMS, MSD, abbVie, roche, novartis, Biogen and Pfizer; consultant for eli lilly; 
speakers' bureau Orion Pharma, Biogen, Pfizer, celltrion, Merck and Samsung 
Bioepis. lJ: lecture and consulting fees from Pfizer, abbvie, novartis, eli-lily and 
Janssen.
Patient consent for publication not required.
ethics approval the appropriate ethical committees and/or data protection 
committees in each country approved of the study (approval codes for Sweden: 
2015/1844-31/2; Denmark: rH-2015–209, i-suite 04145; norway: 2011/1339 
and 2017/243; Finland: 73/13/03/00/2014; and iceland: VSnb2017010049/03.01). 
individual patient consent was not required.
Provenance and peer review not commissioned; externally peer reviewed.
data availability statement all data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access this is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY-nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId ids
Ulf lindström http:// orcid. org/ 0000- 0002- 2250- 9348
Bente glintborg http:// orcid. org/ 0000- 0002- 8931- 8482
RefeRences
 1 Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, 
parallel-group study to demonstrate equivalence in efficacy 
and safety of CT-P13 compared with innovator infliximab when 
coadministered with methotrexate in patients with active rheumatoid 
arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613–20.
 2 Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, 
multicentre, parallel-group, prospective study comparing the 
pharmacokinetics, safety, and efficacy of CT-P13 and innovator 
infliximab in patients with ankylosing spondylitis: the PLANETAS 
study. Ann Rheum Dis 2013;72:1605–12.
 3 Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, 
double-blind, parallel-group study comparing Sb4 with etanercept 
reference product in patients with active rheumatoid arthritis despite 
methotrexate therapy. Ann Rheum Dis 2017;76:51–7.
 4 European Medicines Agency. Available: http://www. ema. europa. eu/ 
ema/ [Accessed Aug 2019].
 5 Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching 
from reference infliximab to CT-P13 compared with maintenance 
of CT-P13 in ankylosing spondylitis: 102-week data from the 
PLANETAS extension study. Ann Rheum Dis 2017;76:346–54.
 6 Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy 
and safety in patients with rheumatoid arthritis continuing on SB4 
or switching from reference etanercept to SB4. Ann Rheum Dis 
2017:annrheumdis-2017-211591.
 7 Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of 
CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: 
comparison between switching from reference infliximab to CT-P13 
and continuing CT-P13 in the PLANETRA extension study. Ann 
Rheum Dis 2017;76:355–63.
 8 Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator 
infliximab to biosimilar CT-P13 compared with maintained treatment 
with originator infliximab (NOR-SWITCH): a 52-week, randomised, 
double-blind, non-inferiority trial. Lancet 2017;389:2304–16.
 9 Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical 
switch from originator infliximab to biosimilar CT-P13 in 802 patients 
with inflammatory arthritis: 1-year clinical outcomes from the 
DANBIO registry. Ann Rheum Dis 2017;76:1426–31.
 10 Benucci M, Gobbi FL, Bandinelli F, et al. Safety, efficacy and 
immunogenicity of switching from innovator to biosimilar infliximab 
in patients with spondyloarthritis: a 6-month real-life observational 
study. Immunol Res 2017;65:419–22.
 11 Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective 
complaints as the main reason for biosimilar discontinuation 
after open-label transition from reference infliximab to biosimilar 
infliximab. Arthritis Rheumatol 2018;70:60–8.
 12 Scherlinger M, Germain V, Labadie C, et al. Switching from originator 
infliximab to biosimilar CT-P13 in real-life: the weight of patient 
acceptance. Joint Bone Spine 2018;85:561–7.
 13 Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect 
challenges the non-medical infliximab switch in practice. Eur J Clin 
Pharmacol 2018;74:655–61.
 14 Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: 
results of a nationwide guideline of mandatory switching from 
originator to biosimilar etanercept. one-year treatment outcomes in 
2061 patients with inflammatory arthritis from the DANBIO registry. 
Ann Rheum Dis 2019;78:192–200.
 15 Nikiphorou E, Hannonen P, Asikainen J, et al. Survival and safety 
of infliximab bio-original and infliximab biosimilar (CT-P13) in usual 
rheumatology care. Clin Exp Rheumatol 2019;37:55–9.
 16 Odinet JS, Day CE, Cruz JL, et al. The Biosimilar nocebo effect? A 
systematic review of double-blinded versus open-label studies. J 
Manag Care Spec Pharm 2018;24:952–9.
 17 Van Spall HGC, Toren A, Kiss A, et al. Eligibility criteria of 
randomized controlled trials published in high-impact general 
medical journals: a systematic sampling review. JAMA 
2007;297:1233–40.
copyright.
 o
n
 N
ovem
ber 28, 2019 at University of Helsinki. Protected by
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001079 on 23 O
ctober 2019. Downloaded from
 
8 lindström U, et al. RMD Open 2019;5:e001079. doi:10.1136/rmdopen-2019-001079
RMD Open
 18 Glintborg B, Lindström U, Aaltonen K, et al. Biological treatment in 
ankylosing spondylitis in the Nordic countries during 2010-2016: a 
collaboration between five biological registries. Scand J Rheumatol 
2018;47:465–74.
 19 Di Giuseppe D, Frisell T, Ernestam S, et al. Uptake of rheumatology 
biosimilars in the absence of forced switching. Expert Opin Biol Ther 
2018;18:499–504.
 20 RADS. The Danish regions rads guidelines for use of biosimilar 
infliximab and etanercept. Available: http://www. regioner. dk/ media/ 
3488/ rads- notat- om- anvendelsen- af- biosimilaere- juni- 2016. pdf 
[Accessed Aug 2019].
 21 Lynge E, Sandegaard JL, Rebolj M. The Danish national patient 
register. Scand J Public Health 2011;39:30–3.
 22 Ludvigsson JF, Andersson E, Ekbom A, et al. External review and 
validation of the Swedish national inpatient register. BMC Public 
Health 2011;11:450.
 23 Dörner T, Strand V, Cornes P, et al. The changing landscape of 
biosimilars in rheumatology. Ann Rheum Dis 2016;75:974–82.
 24 Kay J, Dörner T, Emery P, et al. Clinical trial and ‘real-world’ data 
support switching from a bio-originator to its biosimilar. Ann Rheum 
Dis 2019:annrheumdis-2018-214994.
 25 Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and 
safety of biosimilar infliximab (CT-P13) after switching from originator 
infliximab: open-label extension of the NOR-SWITCH trial. J Intern 
Med 2019;285:653–69.
copyright.
 o
n
 N
ovem
ber 28, 2019 at University of Helsinki. Protected by
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001079 on 23 O
ctober 2019. Downloaded from
 
